tbuckley/cabot-search huggingface dataset:
Abstract 6270: How Many Guidelines Does it Take to Send an Asymptomatic Man to Invasive Angiography?
Authors: Miguel A Leal, Jon G Keevil
Journal: Circulation (2008)

Modern medical practice utilizes peer-reviewed published guidelines in order to establish if a diagnostic test or therapeutic intervention is appropriate and will likely promote better outcomes in patient care. However, some evidence-based recommendations may lead to incremental health care cost and potential patient harm if applied blindly, without the guidance of clinical judgment. To analyze the epidemiologic impact of applying the diagnostic algorithm for coronary artery disease (CAD) management suggested by the Screening for Heart Attack Prevention and Education (SHAPE) task force. Using data from the National Health and Nutrition Examination Survey (NHANES) and the Multi-Ethnic Study of Atherosclerosis (MESA), we assessed the hypothesis that proceeding with further diagnostic evaluation via stress testing in patients who have a coronary calcium score greater than 400 on CT scanning would lead to a remarkable number of invasive procedures performed in an asymptomatic population who is deemed to have low risk for cardiovascular events according to other published guidelines. According to the MESA database and the NHANES data collected up to 2002, 4.6 million American men between ages 45 and 79-years-old have a calcium score greater than 400 on coronary CT imaging, which corresponds to approximately 12 % of the population in that group. Potentially 10 to 12 % of those asymptomatic individuals could have false positive stress tests, leading to almost half a million cardiac catheterizations performed in asymptomatic adult males, with a sizable absolute number of procedure-related cost and complications. The decision to follow diagnostic algorithms in the care of patients with risk factors for coronary artery disease should focus great attention to the type of population being studied, the pre-test probability of disease, the cost-benefit relationship and the risk-benefit ratio. If these epidemiologic and health policy parameters are ignored or underestimated, the feasibility of medical practice (using coronary artery disease management as an example) could be compromised in the long-term, despite minimal or no deviation from established standards of care.
EXPERIMENTAL ARTERIOSCLEROSIS FROM ADRENALIN.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Emergency Resuscitation
Authors: M. H. Brook, J. Brook, G. M. Wyant
Journal: BMJ (1962)

An accident or sudden illness which impairs respiration and/or circulation may result in potentially reversible death, when the victim's heart is too good to die.Respiratory obstruction or apnoea may complicate the unconscious state resulting from an accident or acute illness.The most common site of upper airway obstruction is the oropharynx.The most common cause of upper airway obstruction is the toneless tongue.Cessation of effective circulation, commonly referred to as cardiac arrest, may be due to ventricular fibrillation or asystole.This condition may complicate ischaemic heart disease, hypoxia due to asphyxia, shock, anaes- thetic overdose, or other drug reactions, electric shock, etc.
TMJ
Authors: C. Scott Williams
Journal: JAMA (2008)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cancer-Related Fatigue Clinical Practice Guidelines in Oncology
Journal: Journal of the National Comprehensive Cancer Network (2003)

The problem of cancer-related fatigue, which affects 70% to 100% of cancer patients, has been exacerbated by the increased use of fatigue-inducing multimodal treatments and dose-dense, dose-intense protocols. In patients with metastatic disease, the prevalence of cancer-related fatigue exceeds 75%, and cancer survivors report that fatigue is a disruptive symptom months or even years after treatment ends. To address the significant problem of cancer-related fatigue, the NCCN convened a panel of experts in the field of fatigue. The Cancer-Related Fatigue Clinical Practice Guidelines synthesize the available research and clinical experience in this field and provide recommendations for patient care. For the most recent version of the guidelines, please visit NCCN.org
NIH Has New Whole-Body Model To Count Radiation
Journal: JAMA (1962)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2618: Use of Myeloperoxidase in Chest Pain Evaluation in The Emergency Department
Authors: Martin Möckel, Reinhold Müller, Christian Lueders, Janett Reiche, Christian Müller, Oliver Danne, Jessie Shih
Journal: Circulation (2007)

Background Elevated levels of myeloperoxidase (MPO) have been reported to indicate adverse outcome in selected patients with chest pain and acute coronary syndrome (ACS) but no data exists on its value in the routine setting of an emergency department (ED). Patients and methods Initial MPO was assessed at admission in 432 consecutive patients presenting to the ED who were evaluated for an acute coronary syndrome. In a subset of 116 patients blood samples were also available after 6 and 12–36 hours. All patients were followed up for six weeks with respect to major adverse cardiac events (MACE) including death, re-admission for heart failure or ACS and unplanned repeat coronary revascularisation. MPO was measured using a fully automated immunoassay in development on the ARCHITECT® platform and its prognostic power was compared with serial cardiac troponin I using cut-offs of 198 pmol/L for MPO and 0.1 μg/L for troponin I. Results Incidence of MACE was 13% in this population. MPO was detectable in all samples with a median of 246.5 (range 18 – 4547) pmol/L at admission. MPO increased significantly after 6h and decreased again after 12–36h. In this low-risk population, initial MPO levels revealed a sensitivity (Sens) of 82.1% and a specificity (Spec) of 37.5% (p&lt;0.0001) for MACE compared with 28.6% Sens and 81.1% Spec (p=0.09 n.s.) for initial troponin I. Sensitivity of both markers improved when available serial information was used (MPO: Sens 96.4, Spec 22.6, p&lt;0.0001; troponin I: Sens 44.6%, Spec 76.1%, p&lt;0.01). In serial troponin I negative patients (n=317), both, initial MPO (Sens 80.6%, Spec 42.7%, p&lt;0.05) and serial MPO (Sens 93.5%, Spec 28.7%, p&lt;0.01) still demonstrated significant discriminatory power. Conclusions MPO has independent prognostic value in unselected patients evaluated for ACS in the ED. However MPO levels vary widely over the first 24h hours and also lack specificity.
JAMA Oncology
Journal: JAMA Oncology (2019)

JAMA Oncology is committed to publishing infl uential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.Mission Statement JAMA Oncology is the defi nitive journal for scientists, clinicians, and trainees in the fi eld of oncology worldwide.Our original, innovative, and timely scientifi c and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers.JAMA Oncology aims to eff ectively convey the fi ndings of important clinical research, major scientifi c breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community.Our goal is that successful communication of new knowledge will ultimately translate to clinical benefi t for people living with and surviving cancer.
Withdrawal of cyanocobalamin
Authors: N M. Davidson
Journal: BMJ (1979)

fetal serum AFP that enters the amniotic fluid in the presence of a normal conceptus.Our results and those of Ruoslahti and colleagues emphasise that the AFP con A- binding assay on amniotic fluid has particular value in detecting the presence of communi- cating fetal abnormalities during the period when amniocenteses are usually performed, between the 14th and 18th weeks, in cases where the elevations of amniotic fluid AFP are equivocal or when gestational aging is uncertain.
Low Molecular Weight Components of Polymers Used in Packaging
Authors: Seymour G. Gilbert
Journal: Environmental Health Perspectives (1975)

The increasing use of polymers in packaging of foods and drugs focuses attention on the possible chronic toxicity relations of migrants from these polymers to the contents. Such migrants can arise from residues and additives in the polymers from manufacturing processes used in fabrication of packages. The origin and chemical nature of potential migrants, the methods of transfer, and principles involved in development of safety criteria for their regulation are discussed.
More medical devices get FDA premarket approval
Journal: JAMA (1980)

Since May 1980, seven more class III medical devices have received premarket approval from the Bureau of Medical Devices of the Food and Drug Administration. This brings to 56 the number of devices that have been so approved, notice of which is also published in the<i>Federal Register</i>. For a summary of safety and effectiveness data on the approved products, or for any comments or questions, physicians may contact Henry Goldstein, HFK-402, Program Management Staff, Bureau of Medical Devices, 8757 Georgia Ave, Silver Spring, MD 20910, or call (301) 427-8162. The seven devices most recently approved are: Mini-Balloon Detachable Catheter System, a vascular catheter with a detachable silicone rubber balloon intended for the permanent occlusion of arteries up to 4 mm in diameter. Manufactured by Becton-Dickinson Co, Rutherford, NJ. Havab-M Diagnostic Kit, a radioimmunoassay for antibody to hepatitis A virus. Made by Abbott Laboratories, North Chicago, Ill.
Equivalence Trials
Authors: James H. Ware, Elliott M. Antman
Journal: New England Journal of Medicine (1997)

In the typical two-group clinical trial with outcomes of either success or failure, investigators are interested in finding out whether an innovative treatment, T, reduces the frequency of failure relative to standard therapy, S. If pT and pS are used to represent the respective frequencies, this question can be answered by testing the null hypothesis of equal efficacy, H0: pT = pS, against the alternative hypothesis of superiority, HA: pT < pS. If the null hypothesis can be rejected in favor of the alternative hypothesis, we conclude that . . .
预测甲氨蝶呤临床疗效的临床因素
Authors: K.X. Yan, Y.J. Zhang, L. Han, Q. Huang, Z.H. Zhang, X. Fang, Z.Z. Zheng, N. Yawalkar, Y.L. Chang, Q. Zhang, L. Jin, D.F. Qian, X.Y. Li, M.S. Wu, Q.H. Xu, X.J. Zhang, J.H. Xu
Journal: British Journal of Dermatology (2019)
Immune Sera. A Concise Exposition of Our Present Knowledge Concerning the Constitution and Mode of Action of Antitoxins, Agglutinins, Hemolysins, Bacteriolysins, Precipitins, Cytotoxins and Opsonins.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Novel Lentiviral Vectors Displaying ‘Early-Acting-Cytokines’ Preferentially Promote the Survival and Transduction of NOD/SCID Repopulating Human Hematopoietic Stem Cells.
Authors: E.L.S. Verhoeyen, Maciej Wiznerowicz, Delphine Olivier, Brigitte Izac, Didier Trono, Anne Dubart-Kupperschmitt, Francois L. Cosset
Journal: Blood (2004)
HGCSG1503: A retrospective cohort study evaluating the safety and efficacy of TAS-102 in patients with metastatic colorectal cancer: Analysis of GERCOR index
Authors: K. Hatanaka, S. Yuki, S. Nakano, K. Sawada, K. Harada, H. Okuda, T. Ando, K. Ogawa, K. Furukawa, S. Minami, T. Saiki, T. Ohta, T. Kato, J. Nakajima, T. Sasaki, S. Saitoh, Y. Shindo, M. Tateyama, S. Kato, H. Nagai, Y. Sakata, Y. Komatsu
Journal: Annals of Oncology (2018)

Introduction: In the treatment for metastatic colorectal cancer (mCRC), it is essential for understanding the prognosis of each individual patient. GERCOR index (GI) based on performance status and serum LDH has been previously proposed. However, in the later line setting, the validity of GI has not been reported in patients treated by TAS-102. Methods: 411 patients with mCRC treated by TAS-102 were retrospectively registered from 28 centers in Japan. Selection criteria for this analysis were: (1) ECOG performance status 0-2, (2) presence of serum LDH before the start of TAS-102, and (3) presence of KRAS mutational status. Univariate and multivariate analysis for overall survival (OS) and progression-free survival (PFS) were performed using patient characteristics. Survival analyses were performed with Kaplan-Meier method, log-rank test and Cox proportional hazards model. Results: In 389 patients, all data were available for prognostic categorization. Median OS and PFS were 7.4 and 2.2 months in this analysis set. The distribution of GI were Low risk (L: n = 64), Intermediate risk (I: n = 158), and High risk (H: n = 167). The median OS of L, I, and H were 13.5, 8.4, and 5.3 months, respectively. For OS, there were significant difference between L and H (p < 0.001), I and H (p < 0.001), and L and I (p = 0.003). The median PFS of L, I, and H were 2.8, 2.6, and 1.9 months, respectively. For PFS, there were significant difference between L and H (p < 0.001), I and H (p = 0.015), and L and I (p = 0.007). In Cox multivariate analysis, GI showed an independent prognostic (L vs I; HR 1.566, p = 0.008/L vs H; HR 2.476, p < 0.001) and predictive impact(L vs I; HR 1.427, p = 0.022/L vs H; HR 1.932, p < 0.001). Conclusion: In this analysis, GI might be a predictive and prognostic factor in later line treatment with TAS-102 for patients with mCRC. The prospective evaluation is needed for the further validation.
Abstract 1679: Neoepitope screening in colorectal cancer patients by custom exome panel profiling somatic mutations
Authors: Raghavee Venkatramanan, Kerry Deutsch, Inah Golez, Pallavi Shroff, Spencer Seale, Brendan Ralph, Sally. Dow, Evan Anderson, Saman Tahir, Anjali Malge, Corey Braastad, Steven Anderson
Journal: Cancer Research (2019)

Abstract Colorectal cancer (CRC) is one of the major causes of global mortality. Recent clinical advances in T cell therapy using antibodies that block inhibitory T cell signals have been transforming cancer therapy. Studies show that somatic mutations in protein coding regions produce tumor-specific antigens, or neoantigens. CRC warrants deeper investigation into the non-synonymous exonic mutations that seem to be drivers in tumor development. Tumor mutation burden (TMB) and the abundance of neoantigens are highly correlated and it has been shown that TMB can be estimated using targeted sequencing panels. The aim of this study is to investigate 10 matched tumor/normal CRC samples using a panel targeting 422 genes covering about 1.7 Mb to screen for potential neoepitope candidates. Although sequencing and bioinformatics pipelines are developed to effectively filter neoantigens, it is still unclear which antigens elicit a T cell response. A review of the tools used in neoepitope prediction shows that it is not only a very complex task, but demands high sequencing depth. Comparing currently available tools will enable us to understand the strengths and shortcomings of each algorithm, and develop a custom pipeline framework. Note: This abstract was not presented at the meeting. Citation Format: Raghavee Venkatramanan, Kerry Deutsch, Inah Golez, Pallavi Shroff, Spencer Seale, Brendan Ralph, Sally. Dow, Evan Anderson, Saman Tahir, Anjali Malge, Corey Braastad, Steven Anderson. Neoepitope screening in colorectal cancer patients by custom exome panel profiling somatic mutations [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1679.
Uterine Hydatids
Authors: T. Mellor
Journal: BMJ (1865)

rules" of this suicidal clause; because simply sui- cide, if regarded from a medical point of view, ought no more to concern the Postmaster-General, or the Government which he represents, than ought the fact of the death of one insured from a fractured skull or a broken leg, typhus fever, erysipelas, heart- disease, or what not; or because the Postmaster-
THE PHYSICIAN AND N R A
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
In Comment
Authors: John C. Ballin
Journal: JAMA (1974)

THE POSSIBLE overuse of antibiotics should be a subject of considerable importance to all physicians in their desire to practice good therapeutics. Unfortunately, the problem of accumulating hard, reliable data documenting widespread improper or excessive use of antibiotics is complex and is confounded by a lack of agreement among authorities as to what constitutes proper usage. Nevertheless, many experts well-versed in antibiotic therapy believe that this group of agents may be the most improperly used class of drugs in all of medicine. It is obvious that Drs. Simmons and Stolley believe that there is gross misuse of antibiotics in the United States. To support their views, they present some data, postulate several hypotheses, and raise a multitude of questions that imply poor therapeutic practice in the use of this important group of drugs. Much of these data are sound, the hypotheses may be correct, and many of the questions appear